Dutasteride - Wikipedia

Dutasteride, sold under the brand name Avodart among others, is a medication primarily used to treat the symptoms of an enlarged prostate. Dutasteride FromWikipedia,thefreeencyclopedia Jumptonavigation Jumptosearch Hormonereplacementmedication DutasterideClinicaldataTradenamesAvodart,others;Combodart,Duodart(withtamsulosin)OthernamesGG-745;GI-198745;GI-198745X;N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamideAHFS/Drugs.comMonographMedlinePlusa603001Licensedata US DailyMed: Dutasteride Pregnancycategory Nottobeusedduringpregnancy RoutesofadministrationBymouthDrugclass5α-ReductaseinhibitorATCcodeG04CB02(WHO)LegalstatusLegalstatus UK:POM(Prescriptiononly) US:℞-only PharmacokineticdataBioavailability60%[1]Proteinbinding99%[1]MetabolismLiver(CYP3A4)[1]Metabolites•4'-Hydroxydutasteride[1]•6'-Hydroxydutasteride[1]•1,2-Dihydrodutasteride[1](Allthreeactive)[1]Eliminationhalf-life4–5weeks[2][3]ExcretionFeces:40%(metabolites)[1]Urine:5%(unchanged)[1]Identifiers IUPACname (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide CASNumber164656-23-9 YPubChemCID6918296IUPHAR/BPS7457DrugBankDB01126 YChemSpider5293502 YUNIIO0J6XJN02IKEGGD03820 YChEBICHEBI:521033 YChEMBLChEMBL1200969 YCompToxDashboard(EPA)DTXSID8046452ECHAInfoCard100.166.372ChemicalandphysicaldataFormulaC27H30F6N2O2Molarmass528.539 g·mol−13Dmodel(JSmol)Interactiveimage SMILES FC(F)(F)c1cc(c(cc1)C(F)(F)F)NC(=O)[C@@H]3[C@]2(CC[C@H]4[C@H]([C@@H]2CC3)CC[C@H]5NC(=O)\C=C/[C@]45C)C InChI InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1 YKey:JWJOTENAMICLJG-QWBYCMEYSA-N Y   (verify) Dutasteride,soldunderthebrandnameAvodartamongothers,isamedicationprimarilyusedtotreatthesymptomsofanenlargedprostate.Afewmonthsmayberequiredbeforebenefitsoccur.[4]Itisalsousedforscalphairlossinmenandasapartofhormonetherapyintransgenderwomen.[5][6]Itistakenorally.[7][8][4] Themostcommonlyreportedsideeffectsofdutasteride,althoughstatisticallyrare,includesexualdysfunction,breasttendernessanddepression.[7]Exposureduringpregnancyisspecificallycontraindicatedbecausedutasteride,beingaformofantiandrogen,mayinterferewiththesexualdifferentiationofthemalefoetus.[3][7] Dutasteridewaspatentedin1993byGlaxoSmithKlineandwasapprovedformedicalusein2001.[9][7]Itisavailableasagenericmedication.[4]In2017,itwasthe276thmostcommonlyprescribedmedicationintheUnitedStates,withmorethanonemillionprescriptions.[10][11] Contents 1Medicaluses 1.1Enlargedprostate 1.2Prostatecancer 1.3Scalphairloss 1.4Excessivehairgrowth 1.5Transgenderhormonetherapy 1.6Availableforms 2Contraindications 3Adverseeffects 4Overdose 5Interactions 6Pharmacology 6.1Pharmacodynamics 6.2Pharmacokinetics 7Chemistry 8History 9Societyandculture 9.1Genericnames 9.2Brandnames 9.3Availability 10Research 11References 12Furtherreading 13Externallinks Medicaluses[edit] Enlargedprostate[edit] Dutasterideisusedfortreatingbenignprostatichyperplasia(BPH);colloquiallyknownasan"enlargedprostate".[8][12]ItisapprovedbytheFoodandDrugAdministration(FDA)intheU.S.forthisindication.[13] Prostatecancer[edit] A2010Cochranereviewfounda25–26%reductionintheriskofdevelopingprostatecancerwith5α-reductaseinhibitorchemoprevention.[14]However,5α-reductaseinhibitorshavebeenfoundtoincreasetheriskofdevelopingcertainrarebutaggressiveformsofprostatecancer(27%riskincrease),althoughnotallstudieshaveobservedthis.[15]Thereisinsufficientdatatodetermineiftheyhaveaneffectontheoverallriskofdeathfromprostatecancer.[15] Scalphairloss[edit] DutasterideisapprovedforthetreatmentofmaleandrogeneticalopeciainSouthKoreaandJapanatadosageof0.5 mgperday.[5][16]Ithasbeenfoundinseveralstudiestoinducehairregrowthinmenmorerapidlyandtoagreaterextentthaneventhehighestapproveddosageoffinasteride.[5][17][18][19]Thesuperioreffectivenessofdutasteriderelativetofinasterideforthisindicationisrelatedtothefactthattheinhibitionof5α-reductaseandconsequentreductionofDHTproductionwithinthehairfolliclesismorecompletewithdutasteride.Dutasterideisalsousedoff-labelinthetreatmentoffemalepatternhairloss.[20][21] Excessivehairgrowth[edit] Althoughnoreportsspecifictodutasteridecurrentlyexist,[22][3]5α-reductaseinhibitorslikefinasteridehavebeenfoundtobeeffectiveinthetreatmentofhirsutism(excessivefacialand/orbodyhairgrowth)inwomen.[3]Inastudyof89womenwithhyperandrogenismduetopersistentadrenarchesyndrome,finasterideproduceda93%reductioninfacialhirsutismanda73%reductioninbodilyhirsutismafter2yearsoftreatment.[3]Otherstudiesusingfinasterideforhirsutismhavealsofoundittobeclearlyeffective.[3]Dutasteridemaybemoreeffectivethanfinasterideforthisindicationduetothefactthatitsinhibitionofthe5α-reductaseenzymeiscomparativelymorecomplete.[1] Transgenderhormonetherapy[edit] Dutasterideissometimesusedasacomponentofhormonetherapyfortransgenderwomenincombinationwithanestrogenand/oranotherantiandrogenlikespironolactone.[6]Itmaybeusefulfortreatingscalphairlossorinthosewhohaveissuestoleratingspironolactone.[6] Availableforms[edit] Dutasterideisprovidedintheformofsoftoil-filledgelatinoralcapsulescontaining0.5 mgdutasterideeach.[23] Contraindications[edit] Womenwhoareorwhomaybecomepregnantshouldnothandlethedrug.Dutasteridecancausebirthdefects,specificallyambiguousgenitaliaandundermasculinization,inmalefetuses.[23][24]Thisisduetoitsantiandrogeniceffectsandisseennaturallyin5α-reductasedeficiency.[24]Assuch,womenwhoarepregnantshouldnevertakedutasteride.[23]Peopletakingdutasterideshouldnotdonatebloodtopreventbirthdefectsifapregnantwomanreceivesbloodand,duetoitslongeliminationhalf-life,shouldalsonotdonatebloodforatleast6 monthsafterthecessationoftreatment.[23] Childrenandpeoplewithknownsignificanthypersensitivity(e.g.,seriousskinreactions,angioedema)todutasterideshouldnottakedutasteride.[23] Adverseeffects[edit] Dutasteridehasoverallbeenfoundtobewelltoleratedinstudiesofbothmenandwomen,producingminimalsideeffects.[15]Adverseeffectsincludeheadacheandgastrointestinaldiscomfort.[15]Isolatedreportsofmenstrualchanges,acne,anddizzinessalsoexist.[15]Thereisasmallriskofgynecomastia(breastdevelopmentorenlargement)inmen.[15]Theriskofgynecomastiawith5α-reductaseinhibitorsisabout2.8%.[25] TheFDAhasaddedawarningtodutasterideaboutanincreasedriskofhigh-gradeprostatecancer.[26]Whilethepotentialforpositive,negativeorneutralchangestothepotentialriskofdevelopingprostatecancerwithdutasteridehasnotbeenestablished,evidencehassuggesteditmaytemporarilyreducethegrowthandprevalenceofbenignprostatetumors,butcouldalsomasktheearlydetectionofprostatecancer.Theprimaryareaforconcernisforpatientswhomaydevelopprostatecancerwhilsttakingdutasterideforbenignprostatichyperplasia,whichinturncoulddelaydiagnosisandearlytreatmentoftheprostatecancer,therebypotentiallyincreasingtheriskofthesepatientsdevelopinghigh-gradeprostatecancer.[27]A2018meta-analysisfoundnohigherriskofbreastcancerwith5α-reductaseinhibitors.[28] Sexualdysfunction,suchaserectiledysfunction,lossoflibido,orreducedsemenvolumearebelievedbymanytobesideeffectsof5α-reductaseinhibitors,occurringinasmanyas4.8%ofallpatients,whichinsomecasesmaypersistafterdiscontinuingmedication,leadingtoalowerqualityoflife.Howeverasof2021thisremainsahighlycontestedtopicintheacademicliterature,andmetareviewarticlesfromcredibleinternationalsourcesdifferonwhetherthisphenomenonisproven,whetheritisapurelyplacebo/noceboeffect,orwhetherthereisnotenoughevidencetoreachaconclusion.[29][30][15][31][32][33]ThePost-FinasterideSyndromeFoundationwascreatedwithamedicaladvisoryboardtostudythetopic(Finasteridebeingasimilar5α-reductaseinhibitor),[34]andlawsuitsallegedingharmfromthedrugareongoing.[35] Severalsmallstudieshavereportedanassociationbetween5α-reductaseinhibitorsanddepression.[15]However,moststudieshavenotobservedthissideeffect.[15]Therehavealsobeenreportsinasubsetofmenoflong-lastingdepressionpersistingevenafterdiscontinuationofdutasteride,althoughthereisnoscientificevidencetosupportsuchaclaim.[33] Overdose[edit] ThereisnospecificantidoteforoverdoseofdutasterideasDutasterideisextremelysafeandwelltolerated.ResearchstudiesshowthatDutasterideisnotlethaldespitetaking100timesthenormaldose.[36]Treatmentofdutasterideoverdoseshouldbebasedonsymptomsandshouldbesupportive.[36]Thelongeliminationhalf-lifeofdutasterideshouldbetakenintoconsiderationintheeventofanoverdoseofthemedication.[36]Dutasteridehasbeenusedinclinicalstudiesatdosesofupto40 mg/dayforaweek(80 timesthetherapeuticdosage)and5 mg/dayfor6 months(10 timesthetherapeuticdosage)withnosignificantsafetyconcernsoradditionalsideeffects,respectively.[36] Interactions[edit] Despiteanyconclusiveresearchstudies,itisthoughtthat5α-reductaseinhibitorslikedutasteridemaypreventtheformationofneurosteroidmetaboliteslikeallopregnanolonefromprogesteroneandhencemaymitigatethepsycho-cognitiveeffectsofprogesterone,particularlyifitisadministeredorally.[37][38][39][40][41] Pharmacology[edit] Pharmacodynamics[edit] Dutasteridebelongstoaclassofdrugscalled5α-reductaseinhibitors,whichblocktheactionofthe5α-reductaseenzymesthatconverttestosteroneintoDHT.[42]Itinhibitsallthreeformsof5α-reductase,andcandecreaseDHTlevelsinthebloodbyupto98%.[1][43][44]Specificallyitisacompetitive,mechanism-based(irreversible)inhibitorofallthreeisoformsof5α-reductase,typesI,II,andIII(IC50valuesare3.9 nMfortypeIand1.8 nMfortypeII).[1][43][45][46]Thisisincontrasttofinasteride,whichissimilarlyanirreversibleinhibitorof5α-reductase[46][47]butonlyinhibitsthetypeIIandIIIisoenzymes.[43]Asaresultofthisdifference,dutasterideisabletoachieveareductionincirculatingDHTlevelsofupto98%,whereasfinasterideisabletoachieveareductionofonly65to70%.[44][2][42][48]InspiteofthedifferentialreductionincirculatingDHTlevels,thetwodrugsdecreaselevelsofDHTtoasimilarextentofapproximately85to90%intheprostategland,[48]wherethetypeIIisoformof5α-reductasepredominates.[45] Since5α-reductasesdegradetestosteronetoDHT,theinhibitionofthemcouldcauseanincreaseintestosterone.However,a2018reviewfoundthatinitiationof5α-reductaseinhibitorsdidnotresultinaconsistentincreaseintestosteronelevels,withsomestudiesshowingincreasesandothersshowingnochange.[49]Therewasnostatisticallysignificantchangeintestosteronelevelsfrom5α-reductaseinhibitorsintheoverallmeta-analysis,thoughmenwithlowerbaselinetestosteronelevelsmayshowariseintestosteronelevels. InadditiontoinhibitionofDHTproduction,5α-reductaseinhibitorslikedutasteridearealsoneurosteroidogenesisinhibitors,preventingthe5α-reductase-mediatedbiosynthesisofvariousneurosteroidsincludingallopregnanolone(fromprogesterone),THDOC(fromdeoxycorticosterone),and3α-androstanediol(fromtestosterone).[50]TheseneurosteroidsarepotentpositiveallostericmodulatorsoftheGABAAreceptorandhavebeenfoundtopossessantidepressant,anxiolytic,andpro-sexualeffectsinanimalresearch.[50][51][52]Forthisreason,preventionofneurosteroidformationmaybeinvolvedinthesexualdysfunctionanddepressionthathasbeenassociatedwith5α-reductaseinhibitorslikedutasteride.[50] Pharmacokinetics[edit] Theoralbioavailabilityofdutasterideisapproximately60%.[1]Fooddoesnotadverselyaffecttheabsorptionofdutasteride.[1]Peakplasmalevelsoccur2to3 hoursafteradministration.[1]Levelsofdutasterideinsemenhavebeenfoundtobe3 ng/mL,withnosignificanteffectsonDHTlevelsinsexualpartners.[1]ThedrugisextensivelymetabolizedintheliverbyCYP3A4.[1]Ithasthreemajormetabolites,including6'-hydroxydutasteride,4'-hydroxydutasteride,and1,2-dihydrodutasteride;theformertwoareformedbyCYP3A4,whilethelatterisnot.[1]Allthreemetabolitesareactive;6'-hydroxydutasteridehassimilarpotencyasa5α-reductaseinhibitortodutasteride,whiletheothertwoarelesspotent.[1]Dutasteridehasanextremelylongterminaloreliminationhalf-lifeofabout4or5 weeks.[2][3]Theeliminationhalf-lifeofdutasterideisincreasedintheelderly(170 hoursformenage20–49 years,300 hoursformenage>70 years).[1]Nodosageadjustmentisnecessaryintheelderlynorinrenalimpairment.[1]Becauseofitslongeliminationhalf-life,dutasteriderequires5or6 monthstoreachsteadystateconcentrations.[45]Italsoremainsinthebodyforalongtimeafterdiscontinuationandcanbedetectedforupto4to6 months.[1][2]Incontrasttodutasteride,finasteridehasashortterminalhalf-lifeofonly5to8 hours.[3][1]Dutasterideiseliminatedmainlyinthefeces(40%)asmetabolites.[1]Asmallportion(5%)iseliminatedunchangedintheurine.[1] Chemistry[edit] Seealso:Listof5α-reductaseinhibitors Dutasteride,alsoknownasN-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide,isasyntheticandrostanesteroidanda4-azasteroid.[53][54]Itisananalogueoffinasterideinwhichthetert-butylamidemoietyhasbeenreplacedwitha2,5-bis(trifluoromethyl)phenylgroup.[54] History[edit] Dutasteridewaspatentedin1996[55]andwasfirstdescribedinthescientificliteraturein1997.[56]ItwasapprovedbytheFDAforthetreatmentofBPHinNovember2001andwasintroducedintotheUnitedStatesmarketthefollowingyearunderthebrandnameAvodart.[56]Dutasteridehassubsequentlybeenintroducedinmanyothercountries,includingthroughoutEuropeandSouthAmerica.[56]ThepatentprotectionofdutasterideexpiredinNovember2015andthedrughassincebecomeavailableintheUnitedStatesinavarietyoflow-costgenericformulations.[55] ItwasapprovedforthetreatmentofscalphairlossinSouthKoreasince2009andinJapansince2015.[57]IthasnotbeenapprovedforthisindicationintheUnitedStates,[5][16]thoughitisoftenusedoff-label.[20] Societyandculture[edit] Avodart(dutasteride)500µgsoftcapsules. Genericnames[edit] DutasterideisthegenericnameofthedrugAvodartandhastheexactsameformula,composedofsevenothermolecularingredientsanditsINN,USAN,BAN,andJAN.[58] Brandnames[edit] DutasterideissoldprimarilyunderthebrandnameAvodartand,incombinationwithtamsulosin(seedutasteride/tamsulosin),underthebrandnamesCombodartandDuodart.[58]Itisalsosoldunderavarietyofgenericbrandnames.[58]DutasterideisalsoavailableincombinationwithalfuzosinunderthebrandnamesAlfusin-DandDutalfa,butonlyinIndia.[58] Availability[edit] Dutasterideisavailablewidelythroughouttheworld,includingintheUnitedStates,Canada,theUnitedKingdom,Ireland,manyotherEuropeancountries,Australia,andSouthAfrica,aswellasinLatinAmerica,Asia,andelsewhere.[58]ItisavailableasagenericmedicationintheUnitedStatesandothercountries.[55] Research[edit] Dutasteridehasbeenstudiedincombinationwithbicalutamideinthetreatmentofprostatecancer.[59][60][61][62][63] Astudyfoundthatdutasteride,whichblockstheformationoftheneurosteroidallopregnanolonefromprogesterone,iseffectiveinreducingsymptomsinwomenwithpremenstrualdysphoricdisorder.[37] References[edit] ^abcdefghijklmnopqrstuvwxyLemkeTL,WilliamsDA(2008).Foye'sPrinciplesofMedicinalChemistry.LippincottWilliams&Wilkins.pp. 1286–1287.ISBN 978-0-7817-6879-5. ^abcdBurchumJ,RosenthalL(2December2014).Lehne'sPharmacologyforNursingCare.ElsevierHealthSciences.pp. 803–.ISBN 978-0-323-34026-7. ^abcdefghBlume-PeytaviU,WhitingDA,TrüebRM(26June2008).HairGrowthandDisorders.SpringerScience&BusinessMedia.pp. 182,369.ISBN 978-3-540-46911-7. ^abcBritishnationalformulary :BNF76(76 ed.).PharmaceuticalPress.2018.p. 769.ISBN 9780857113382. ^abcdShapiroJ,OtbergN(17April2015).HairLossandRestoration,SecondEdition.CRCPress.pp. 39–.ISBN 978-1-4822-3199-1. ^abcWespLM,DeutschMB(March2017)."HormonalandSurgicalTreatmentOptionsforTransgenderWomenandTransfeminineSpectrumPersons".ThePsychiatricClinicsofNorthAmerica.40(1):99–111.doi:10.1016/j.psc.2016.10.006.PMID 28159148. ^abcd"DutasterideMonographforProfessionals".Drugs.com.AmericanSocietyofHealth-SystemPharmacists.Retrieved18March2019. ^abWuC,KapoorA(July2013)."Dutasterideforthetreatmentofbenignprostatichyperplasia".ExpertOpiniononPharmacotherapy.14(10):1399–408.doi:10.1517/14656566.2013.797965.PMID 23750593.S2CID 25041466. ^FischerJ,GanellinCR(2006).Analogue-basedDrugDiscovery.JohnWiley&Sons.p. 483.ISBN 9783527607495. ^"TheTop300of2020".ClinCalc.Retrieved11April2020. ^"Dutasteride-DrugUsageStatistics".ClinCalc.Retrieved11April2020. ^SlaterS,DumasC,BubleyG(March2012)."Dutasterideforthetreatmentofprostate-relatedconditions".ExpertOpiniononDrugSafety.11(2):325–30.doi:10.1517/14740338.2012.658040.PMID 22316171.S2CID 207487490. ^"Drugs@FDA:FDAApprovedDrugProducts".www.accessdata.fda.gov. ^WiltTJ,MacdonaldR,HagertyK,SchellhammerP,TacklindJ,SomerfieldMR,KramerBS(November2010)."5-α-Reductaseinhibitorsforprostatecancerchemoprevention:anupdatedCochranesystematicreview".BJUInternational.106(10):1444–51.doi:10.1111/j.1464-410X.2010.09714.x.PMID 20977593.S2CID 22178061. ^abcdefghiHirshburgJM,KelseyPA,TherrienCA,GavinoAC,ReichenbergJS(July2016)."AdverseEffectsandSafetyof5-alphaReductaseInhibitors(Finasteride,Dutasteride):ASystematicReview".TheJournalofClinicalandAestheticDermatology.9(7):56–62.PMC 5023004.PMID 27672412. ^abChoiGS,KimJH,OhSY,ParkJM,HongJS,LeeYS,LeeWS(August2016)."SafetyandTolerabilityoftheDual5-AlphaReductaseInhibitorDutasterideintheTreatmentofAndrogeneticAlopecia".AnnalsofDermatology.28(4):444–50.doi:10.5021/ad.2016.28.4.444.PMC 4969473.PMID 27489426. ^Dhurat,Rachita;Sharma,Aseem;Rudnicka,Lidia;Kroumpouzos,George;Kassir,Martin;Galadari,Hassan;Wollina,Uwe;Lotti,Torello;Golubovic,Masa;Binic,Iva;Grabbe,Stephan;Goldust,Mohamad(May2020)."5‐Alphareductaseinhibitorsinandrogeneticalopecia:Shiftingparadigms,currentconcepts,comparativeefficacy,andsafety".DermatologicTherapy.33(3):e13379.doi:10.1111/dth.13379.PMID 32279398.S2CID 215748750. ^ZhouZ,SongS,GaoZ,WuJ,MaJ,CuiY(2019)."Theefficacyandsafetyofdutasteridecomparedwithfinasterideintreatingmenwithandrogeneticalopecia:asystematicreviewandmeta-analysis".ClinicalInterventionsinAging.14:399–406.doi:10.2147/CIA.S192435.PMC 6388756.PMID 30863034. ^Olsen,EliseA.;Hordinsky,Maria;Whiting,David;Stough,Dow;Hobbs,Stuart;Ellis,MelissaL.;Wilson,Timothy;Rittmaster,RogerS.;DutasterideAlopeciaResearch,Team.(December2006)."Theimportanceofdual5α-reductaseinhibitioninthetreatmentofmalepatternhairloss:Resultsofarandomizedplacebo-controlledstudyofdutasterideversusfinasteride".JournaloftheAmericanAcademyofDermatology.55(6):1014–1023.doi:10.1016/j.jaad.2006.05.007.PMID 17110217. ^abNusbaumAG,RosePT,NusbaumBP(August2013)."Nonsurgicaltherapyforhairloss".FacialPlasticSurgeryClinicsofNorthAmerica.21(3):335–42.doi:10.1016/j.fsc.2013.04.003.PMID 24017975. ^CarminaE,AzzizR,BergfeldW,Escobar-MorrealeHF,FutterweitW,HuddlestonH,et al.(July2019)."FemalePatternHairLossandAndrogenExcess:AReportFromtheMultidisciplinaryAndrogenExcessandPCOSCommittee".TheJournalofClinicalEndocrinologyandMetabolism.104(7):2875–2891.doi:10.1210/jc.2018-02548.PMID 30785992. ^LebwohlMG,HeymannWR,Berth-JonesJ,CoulsonI(19September2013).TreatmentofSkinDisease:ComprehensiveTherapeuticStrategies.ElsevierHealthSciences.pp. 327–.ISBN 978-0-7020-5236-1. ^abcde"FDAprescribinginformation"(PDF).June2011.Retrieved15September2013. ^abMcVaryKT,WelliverC(12August2016).TreatmentofLowerUrinaryTractSymptomsandBenignProstaticHyperplasia:Currentmethods,outcomes,andcontroversies,AnIssueofUrologicClinicsofNorthAmerica,E-Book.ElsevierHealthSciences.pp. 396–.ISBN 978-0-323-45994-5. ^TrostL,SaitzTR,HellstromWJ(May2013)."SideEffectsof5-AlphaReductaseInhibitors:AComprehensiveReview".SexualMedicineReviews.1(1):24–41.doi:10.1002/smrj.3.PMID 27784557. ^"FDADrugSafetyCommunication:5-alphareductaseinhibitors(5-ARIs)mayincreasetheriskofamoreseriousformofprostatecancer".U.S.FoodandDrugAdministration.18June2019. ^WalshPC(April2010)."Chemopreventionofprostatecancer".TheNewEnglandJournalofMedicine.362(13):1237–8.doi:10.1056/NEJMe1001045.PMID 20357287. ^WangJ,ZhaoS,LuoL,LiE,LiX,ZhaoZ(2018)."5-alphaReductaseInhibitorsandriskofmalebreastcancer:asystematicreviewandmeta-analysis".InternationalBrazJUrol.44(5):865–873.doi:10.1590/S1677-5538.IBJU.2017.0531.PMC 6237523.PMID 29697934. ^Traish,AbdulmagedM.(January2020)."Post-finasteridesyndrome:asurmountablechallengeforclinicians".FertilityandSterility.113(1):21–50.doi:10.1016/j.fertnstert.2019.11.030.PMID 32033719.S2CID 211064052. ^Fertig,Raymond;Shapiro,Jerry;Bergfeld,Wilma;Tosti,Antonella(2017)."InvestigationofthePlausibilityof5-Alpha-ReductaseInhibitorSyndrome".SkinAppendageDisorders.2(3–4):120–129.doi:10.1159/000450617.PMC 5264352.PMID 28232919. ^LiuL,ZhaoS,LiF,LiE,KangR,LuoL,et al.(September2016)."Effectof5α-ReductaseInhibitorsonSexualFunction:AMeta-AnalysisandSystematicReviewofRandomizedControlledTrials".TheJournalofSexualMedicine.13(9):1297–1310.doi:10.1016/j.jsxm.2016.07.006.PMID 27475241. ^POP,ANCA;KISS,BELA;LOGHIN,FELICIA(2013)."Endocrinedisruptingeffectsofbutylatedhydroxyanisole(BHA-E320)".ClujulMedical.86(1):16–20.PMC 4462476.PMID 26527908. ^abTraishAM,HassaniJ,GuayAT,ZitzmannM,HansenML(March2011)."Adversesideeffectsof5α-reductaseinhibitorstherapy:persistentdiminishedlibidoanderectiledysfunctionanddepressioninasubsetofpatients".TheJournalofSexualMedicine.8(3):872–84.doi:10.1111/j.1743-6109.2010.02157.x.PMID 21176115. ^"ThePost-FinasterideSyndromeFoundation–DedicatedtosupportingresearchandfindingtreatmentsforPFSpatientsworldwide".Retrieved2021-12-24. ^Pierson,Brendan(2021-09-08)."Groupsuestohavehair-lossdrugPropeciapulledfrommarket".Reuters.Retrieved2021-12-24. ^abcd"Prescribinginformation"(PDF).www.accessdata.fda.gov.Retrieved2020-01-10. ^abPearlsteinT(April2016)."TreatmentofPremenstrualDysphoricDisorder:TherapeuticChallenges".ExpertReviewofClinicalPharmacology.9(4):493–496.doi:10.1586/17512433.2016.1142371.PMID 26766596.Arecentstudywitha5α-reductaseinhibitordutasteride,thatblockstheconversionofprogesteronetoALLO,reportedthatdutasteride2.5mgdailydecreasedseveralpremenstrualsymptoms ^GoletianiNV,KeithDR,GorskySJ(October2007)."Progesterone:reviewofsafetyforclinicalstudies".ExperimentalandClinicalPsychopharmacology.15(5):427–44.doi:10.1037/1064-1297.15.5.427.PMID 17924777. ^Wang-ChengR,NeunerJM,BarnabeiVM(2007).Menopause.ACPPress.p. 97.ISBN 978-1-930513-83-9. ^BergemannN,Ariecher-RösslerA(27December2005).EstrogenEffectsinPsychiatricDisorders.SpringerScience&BusinessMedia.p. 179.ISBN 978-3-211-27063-9. ^BäckströmT,BixoM,JohanssonM,NybergS,OssewaardeL,RagagninG,et al.(February2014)."Allopregnanoloneandmooddisorders".ProgressinNeurobiology.113:88–94.doi:10.1016/j.pneurobio.2013.07.005.PMID 23978486.S2CID 207407084. ^abBostwickDG,ChengL(24January2014).UrologicSurgicalPathology.ElsevierHealthSciences.pp. 492–.ISBN 978-0-323-08619-6. ^abcYamanaK,LabrieF,Luu-TheV(August2010)."Humantype35α-reductaseisexpressedinperipheraltissuesathigherlevelsthantypes1and2anditsactivityispotentlyinhibitedbyfinasterideanddutasteride".HormoneMolecularBiologyandClinicalInvestigation.2(3):293–9.doi:10.1515/hmbci.2010.035.PMID 25961201.S2CID 28841145. ^abBradburyR(30January2007).Cancer.SpringerScience&BusinessMedia.pp. 49–.ISBN 978-3-540-33120-9. ^abcKeamSJ,ScottLJ(2008)."Dutasteride:areviewofitsuseinthemanagementofprostatedisorders".Drugs.68(4):463–85.doi:10.2165/00003495-200868040-00008.PMID 18318566. ^abGisleskogPO,HermannD,Hammarlund-UdenaesM,KarlssonMO(December1998)."Amodelfortheturnoverofdihydrotestosteroneinthepresenceoftheirreversible5alpha-reductaseinhibitorsGI198745andfinasteride".ClinicalPharmacologyandTherapeutics.64(6):636–47.doi:10.1016/S0009-9236(98)90054-6.PMID 9871428.S2CID 42901328. ^KeserüG,SwinneyDC(28July2015).ThermodynamicsandKineticsofDrugBinding.Wiley.pp. 165–.ISBN 978-3-527-67304-9. ^abHeesakkersJ,ChappleC,DeRidderD,FaragF(24February2016).PracticalFunctionalUrology.Springer.pp. 280–.ISBN 978-3-319-25430-2. ^TraishAM,KrakowskyY,DorosG,MorgentalerA(January2019)."Do5α-ReductaseInhibitorsRaiseCirculatingSerumTestosteroneLevels?AComprehensiveReviewandMeta-AnalysistoExplainingParadoxicalResults".SexualMedicineReviews.7(1):95–114.doi:10.1016/j.sxmr.2018.06.002.PMID 30098986. ^abcTraishAM,MulgaonkarA,GiordanoN(June2014)."Thedarksideof5α-reductaseinhibitors'therapy:sexualdysfunction,highGleasongradeprostatecanceranddepression".KoreanJournalofUrology.55(6):367–79.doi:10.4111/kju.2014.55.6.367.PMC 4064044.PMID 24955220. ^WeizmanA(1February2008).NeuroactiveSteroidsinBrainFunction,BehaviorandNeuropsychiatricDisorders:NovelStrategiesforResearchandTreatment.SpringerScience&BusinessMedia.ISBN 978-1-4020-6854-6. ^TvrdeićA,PoljakL(2016)."Neurosteroids,GABAAreceptorsandneurosteroidbaseddrugs:arewewitnessingthedawnofthenewpsychiatricdrugs?".EndocrineOncologyandMetabolism.2(1):60–71.doi:10.21040/eom/2016.2.7. ^LemkeTL,WilliamsDA(24January2012).Foye'sPrinciplesofMedicinalChemistry.LippincottWilliams&Wilkins.pp. 1381–.ISBN 978-1-60913-345-0. ^abEnriqueRavina(11January2011).TheEvolutionofDrugDiscovery:FromTraditionalMedicinestoModernDrugs.JohnWiley&Sons.pp. 183–.ISBN 978-3-527-32669-3. ^abc"GenericAvodartAvailability".Drugs.com. ^abcLlewellynW(2011).Anabolics.MolecularNutritionLlc.pp. 968–,971–.ISBN 978-0-9828280-1-4. ^MacDonaldG."GSKJapandelaysalopeciadruglaunchafterCatalentmanufacturinghalt". ^abcde"Dutasteride".Drugs.com. ^MerrickGS,ButlerWM,WallnerKE,GalbreathRW,AllenZA,KurkoB(July2006)."Efficacyofneoadjuvantbicalutamideanddutasterideasacytoreductiveregimenbeforeprostatebrachytherapy".Urology.68(1):116–20.doi:10.1016/j.urology.2006.01.061.PMID 16844453. ^SartorO,GomellaLG,GagnierP,MelichK,DannR(October2009)."Dutasterideandbicalutamideinpatientswithhormone-refractoryprostatecancer:theTherapyAssessedbyRisingPSA(TARP)studyrationaleanddesign".TheCanadianJournalofUrology.16(5):4806–12.PMID 19796455. ^ChuFM,SartorO,GomellaL,RudoT,SomervilleMC,HereghtyB,ManyakMJ(August2015)."Arandomised,double-blindstudycomparingtheadditionofbicalutamidewithorwithoutdutasteridetoGnRHanaloguetherapyinmenwithnon-metastaticcastrate-resistantprostatecancer".EuropeanJournalofCancer.51(12):1555–69.doi:10.1016/j.ejca.2015.04.028.PMID 26048455. ^GaudetM,VigneaultÉ,FosterW,MeyerF,MartinAG(January2016)."Randomizednon-inferioritytrialofBicalutamideandDutasterideversusLHRHagonistsforprostatevolumereductionpriortoI-125permanentimplantbrachytherapyforprostatecancer".RadiotherapyandOncology.118(1):141–7.doi:10.1016/j.radonc.2015.11.022.PMID 26702991. ^DijkstraS,WitjesWP,RoosEP,VijverbergPL,GeboersAD,BruinsJL,et al.(2016)."TheAVOCATstudy:Bicalutamidemonotherapyversuscombinedbicalutamideplusdutasteridetherapyforpatientswithlocallyadvancedormetastaticcarcinomaoftheprostate-along-termfollow-upcomparisonandqualityoflifeanalysis".SpringerPlus.5:653.doi:10.1186/s40064-016-2280-8.PMC 4870485.PMID 27330919. Furtherreading[edit] FryeSV(2006)."Discoveryandclinicaldevelopmentofdutasteride,apotentdual5alpha-reductaseinhibitor".CurrentTopicsinMedicinalChemistry.6(5):405–21.doi:10.2174/156802606776743101.PMID 16719800. Externallinks[edit] "Dutasteride".DrugInformationPortal.U.S.NationalLibraryofMedicine. vteAndrogensandantiandrogensAndrogens(incl.AAS)ARagonists Testosteronederivatives:Androstenedioldipropionate Boldenoneundecylenate Clostebol Clostebolacetate Clostebolcaproate Clostebolpropionate Cloxotestosteroneacetate Prasterone(dehydroepiandrosterone,DHEA) Prasteroneenanthate(DHEAenanthate) Prasteronesulfate(DHEAsulfate) Quinbolone Testosterone# Testosteroneesters(e.g.,testosteronecypionate,testosteroneenanthate,testosteronepropionate,testosteroneundecanoate,testosteroneestermixtures(Deposterona,Omnadren,Sustanon,TestovironDepot)) Dihydrotestosteronederivatives:Androstanolone(stanolone,dihydrotestosterone,DHT) Androstanoloneesters Bolazinecapronate Drostanolonepropionate(dromostanolonepropionate) Epitiostanol Mepitiostane Mesterolone Metenoloneacetate(methenoloneacetate) Metenoloneenanthate(methenoloneenanthate) Stenboloneacetate 19-Nortestosteronederivatives:Bolandioldipropionate Nandroloneesters(e.g.,nandrolonedecanoate,nandrolonephenylpropionate) Norclostebol Norclostebolacetate Oxabolonecipionate(oxabolonecypionate) Trenboloneacetate Trenbolonehexahydrobenzylcarbonate(trenbolonecyclohexylmethylcarbonate) 17α-Alkylatedtestosteronederivatives:Bolasterone Calusterone Chlorodehydromethyltestosterone(CDMT) Fluoxymesterone Formebolone Metandienone(methandienone,methandrostenolone) Methandriol(methylandrostenediol) Methandriolbisenanthoylacetate Methandrioldipropionate Methandriolpropionate Methyltestosterone Methyltestosterone3-hexylether Oxymesterone Penmesterol Tiomesterone(thiomesterone) 17α-Alkylateddihydrotestosteronederivatives:Androisoxazole Furazabol Mebolazine(dimethazine) Mestanolone Oxandrolone Oxymetholone Stanozolol 17α-Alkylated19-nortestosteronederivatives:Ethylestrenol Mibolerone Norethandrolone Normethandrone(methylestrenolone,normethisterone) Propetandrol(propethandrol) 17α-Vinyltestosteronederivatives:Norvinisterone(vinylnortestosterone) 17α-Ethynyltestosteronederivatives:Danazol Gestrinone Progestins(e.g.,ethisterone(ethynyltestosterone),levonorgestrel,norgestrel,norethisterone(norethindrone),lynestrenol,norgestrienone) Tibolone Progesteronederivatives:Medroxyprogesteroneacetate Progonadotropins Antiestrogens(e.g.,tamoxifen,clomifene) GnRHagonists(e.g.,GnRH(gonadorelin),leuprorelin) Gonadotropins(e.g.,LH,hCG) AntiandrogensARantagonists Steroidal:Abirateroneacetate Canrenone Chlormadinoneacetate Cyproteroneacetate Delmadinoneacetate Dienogest Drospirenone Medrogestone Megestrolacetate Nomegestrolacetate Osateroneacetate Oxendolone Potassiumcanrenoate Spironolactone Nonsteroidal:Apalutamide Bicalutamide Cimetidine Darolutamide Enzalutamide Flutamide Ketoconazole Nilutamide Seviteronel† Topilutamide(fluridil) Steroidogenesisinhibitors5α-Reductase Alfatradiol Dutasteride Epristeride Finasteride Sawpalmettoextract Others Abirateroneacetate Aminoglutethimide Bifluranol Cyproteroneacetate Flutamide Ketoconazole Nilutamide Seviteronel† Spironolactone Antigonadotropins D2receptorantagonists(prolactinreleasers)(e.g.,domperidone,metoclopramide,risperidone,haloperidol,chlorpromazine,sulpiride) Estrogens(e.g.,bifluranol,diethylstilbestrol,estradiol,estradiolesters,ethinylestradiol,ethinylestradiolsulfonate,paroxypropione) GnRHagonists(e.g.,leuprorelin) GnRHantagonists(e.g.,cetrorelix) Progestogens(incl.,chlormadinoneacetate,cyproteroneacetate,hydroxyprogesteronecaproate,gestonoronecaproate,medroxyprogesteroneacetate,megestrolacetate) Others Androstenedioneimmunogens:Androvax(androstenedionealbumin) Ovandrotonealbumin(Fecundin) #WHO-EM ‡Withdrawnfrommarket Clinicaltrials: †PhaseIII §NevertophaseIII Seealso Androgenreceptormodulators Estrogensandantiestrogens Progestogensandantiprogestogens Listofandrogens/anabolicsteroids vteDrugsusedinbenignprostatichyperplasia(G04C)5α-Reductaseinhibitors Dutasteride Epristeride Finasteride(+tadalafil) Alpha-1blockers Alfuzosin Doxazosin Silodosin Tamsulosin Terazosin Steroidalantiandrogens Allylestrenol Delmadinoneacetate Gestonoronecaproate Osateroneacetate Oxendolone Herbalproducts Pygeumafricanum Sawpalmettoextract Others Mepartricin vteOtherdermatologicalpreparations(D11)Anti-seborrheics Antiandrogens Bicalutamide Cyproteroneacetate Flutamide Spironolactone Antifungals Bifonazole Cetrimoniumbromide(cetrimide) Ciclopiroxolamine(ciclopirox) Climbazole Clotrimazole Ketoconazole Miconazole Piroctoneolamine Seleniumdisulfide(seleniumsulfide) Xenysalate Zincpyrithione(pyrithionezinc) Antihistamines Calcineurininhibitors Cyclosporin Pimecrolimus Tacrolimus Isotretinoin Keratolytics Coaltar Resorcinol Salicylicacid Sulfur Urea(urea-containingcream) Lithiumsalts Lithiumgluconate Lithiumsuccinate Topicalcorticosteroids(e.g.,hydrocortisone) Skinlightening Hydroquinone Mequinol Monobenzone Skindarkening Afamelanotide MelanotanII Anti-inflammatories Oxaceprol Gamolenicacid Pimecrolimus Tacrolimus Alitretinoin Topicalcorticosteroids(e.g.,hydrocortisone) Alopeciatreatments 5α-Reductaseinhibitors Alfatradiol Dutasteride Finasteride Sawpalmettoextract Antiandrogens Bicalutamide Cyproteroneacetate Flutamide Spironolactone Topilutamide(fluridil) Potassiumchannelopeners Minoxidil Others Nepidermin Hairgrowthinhibitors 5α-Reductaseinhibitors Dutasteride Finasteride Antiandrogens Bicalutamide Cyproteroneacetate Flutamide Spironolactone Eflornithine Others Androgens(e.g.,testosterone) Brimonidine Calciumgluconate Estrogens(e.g.,estradiol) Hyaluronicacid Magnesiumsulfate Pregnenoloneacetate Progestogens(e.g.,progesterone) Povidone-iodine Tiratricol vteGlaxoSmithKlineSubsidiaries GlaxoSmithKlinePakistan GlaxoSmithKlinePharmaceuticalsLtd StiefelLaboratories Tesaro ViiVHealthcare(85%) Predecessors,acquisitions Allen&Hanburys BeechamGroup BlockDrug BurroughsWellcome Glaxo GlaxoWellcome HumanGenomeSciences RechercheetIndustrieThérapeutiques ReliantPharmaceuticals S.E.MassengillCompany SmithKlineBeecham Smith,Kline&French ProductsCurrentPharma Advair Alli Augmentin Avandia Beconase Boniva Flixonase Hycamtin Lamictal Paxil/Seroxat Serlipet Tagamet Ventolin Wellbutrin/Zyban Zantac…more Vaccines Hepatyrix Pandemrix Shingrix Twinrix Other Aquafresh Centrum Horlicks Nicoderm Nicorette NiQuitin Sensodyne Tums…more Former BCPowder Geritol Goody'sPowder Lucozade Ribena PeopleBoardofDirectors PhilipHampton EmmaWalmsley SimonDingemans RoyM.Anderson ManvinderBanga PatrickVallance VivienneCox LynnElsenhans JesseGoodman JudyLewent UrsRohner LaurieGlimcher Other ThomasBeecham SilasM.Burroughs MahlonKline JohnK.Smith HenryWellcome AndrewWitty ChrisGent Litigation Canadav.GlaxoSmithKlineInc. Christopherv.SmithKlineBeechamCorp. GlaxoSmithKlineServicesUnlimitedvCommission UnitedStatesv.GlaxoGroupLtd. UnitedStatesv.GlaxoSmithKline Other DrugIndustryDocumentsArchive GlaxoSmithKlinePrize SideEffects Study329 Category Portal:Medicine Retrievedfrom"https://en.wikipedia.org/w/index.php?title=Dutasteride&oldid=1076982077" Categories:5α-ReductaseinhibitorsAndrostanesCarboxamidesDiketonesHairlossmedicationsHairremovalHormonalantineoplasticdrugsLactamsProstatecancerTeratogensTrifluoromethylcompoundsHiddencategories:ArticleswithshortdescriptionShortdescriptionmatchesWikidataECHAInfoCardIDfromWikidataWikipediamedicinearticlesreadytotranslate Navigationmenu Personaltools NotloggedinTalkContributionsCreateaccountLogin Namespaces ArticleTalk English Views ReadEditViewhistory More Search Navigation MainpageContentsCurrenteventsRandomarticleAboutWikipediaContactusDonate Contribute HelpLearntoeditCommunityportalRecentchangesUploadfile Tools WhatlinkshereRelatedchangesUploadfileSpecialpagesPermanentlinkPageinformationCitethispageWikidataitem Print/export DownloadasPDFPrintableversion Inotherprojects WikimediaCommons Languages العربيةCymraegDeutschEspañolفارسیBahasaIndonesiaItalianoNederlands日本語ଓଡ଼ିଆPolskiСрпски/srpskiSrpskohrvatski/српскохрватскиSuomiTürkçeУкраїнськаTiếngViệt Editlinks